Navigation Links
Jazz Pharmaceuticals Announces Paragraph IV ANDA Filing for Xyrem
Date:10/5/2010

PALO ALTO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the website of the US Food and Drug Administration indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Xyrem® (sodium oxybate oral solution) 500 mg/ml was submitted on July 8, 2010.  Jazz Pharmaceuticals has not received a Paragraph IV certification with respect to this filing.

Jazz Pharmaceuticals intends to vigorously enforce its intellectual property rights.  Xyrem is protected by seven patents covering its formulation and the company's distribution system for the product, including five patents listed in the FDA's Approved Drug Products List (the Orange Book).  

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, Jazz Pharmaceuticals' intent to vigorously enforce its intellectual property rights.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of the company to protect its intellectual property and defend its patents, the possible introduction of generic products, the dependence of the company on sale
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies
2. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
3. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
6. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
9. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
10. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
11. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
(Date:7/24/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the Company will issue ... 2014 on Monday, August 18, 2014 for shareholders. Management ... on Monday, August 18, 2014 to discuss the company,s ... CEO, Anthony Hayes . Following prepared ...
(Date:7/24/2014)... As part of the long-term strategic ... MENA region during 2014 with potential global expansion. , ... with DZS to manage our clinical trials globally and ... of R&D and President of SBI pharmaceuticals MENA, Dr. ... with a focus on utilizing eClinical software and flexible ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... New Haven, Conn.A team led by Yale University scientists ... different cells in the blood using magnetizable liquids. The ... 7 in the online edition of the Proceedings ... improve the speed and sensitivity of tests used to ...
... quickly produce ultra-lightweight, bendable batteries and supercapacitors in ... a sheet of paper with ink made of ... conductive storage device, said Yi Cui, assistant professor ... needs a low-cost, high-performance energy storage device, such ...
... , QUINCY, Mass., ... International), a leading biotech developer and manufacturer of renewable biochemicals, ... to receive up to $50 million for its planned biobased ... integrated biorefinery projects that won funding or loan guarantees, Myriant ...
Cached Biology Technology:New technology could boost disease detection tests' speed and sensitivity 2Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... most promising technological research projects at University System of ... cash to help them through the most difficult phase ... With $5.1 million in federal funding, the Maryland ... research institutions and the U.S. Army Research Laboratory (ARL), ...
... one way when crammed together like sardines in a can. ... seat is empty and they have more personal space. Scientists ... involved in health and disease inside living cells. The cover ... (C&EN), ACS, weekly newsmagazine, focuses on how the study of ...
... Rensselaer Polytechnic Institute Professor Georges Belfort has ... of separations processes in biochemical engineering. Belfort, ... Engineering at Rensselaer, in recent weeks received the ... of Biological Products from the American Chemical Society ...
Cached Biology News:$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2
... LVF-HL, LVF-CUVADPT, FHS-LVF, and the CVD-Diffuse ... Linear Variable Filters to create the world's ... wavelength and adjustable bandpass. Each filter features ... band (99.8%). These filters -- with ...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Request Info...
MW5...
Biology Products: